GAITHERSBURG, Md., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Scott Harris, Chief Medical Officer at Altimmune, will present body composition data from the Phase 2 MOMENTUM trial of pemvidutide in the treatment of obesity and participate in a panel discussion at the Cachexia Regulatory & Trials Update Workshop of the 17th International Conference of the Society on Sarcopenia, Cachexia & Wasting Disorders in Washington, D.C.  

Details for the panel discussion are as follows:

Title:Muscle Wasting in Weight Loss Therapy
Session:Treatment Approaches to Address Muscle Wasting in the Context of Obesity Therapy & Regulatory Issues
Presenter:Scott Harris, M.D., Chief Medical Officer, Altimmune, Inc.
Date/Time:Friday, December 6, 2024 at 9:30 am ET
About Altimmune

Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH.  For more information, please visit www.altimmune.com. 

Follow @Altimmune, Inc. on LinkedIn

Get the latest news
delivered to your inbox
Sign up for The Manila Times newsletters
By signing up with an email address, I acknowledge that I have read and agree to the Terms of Service and Privacy Policy.

Follow @AltimmuneInc on Twitter

Company Contact:

Greg Weaver

Chief Financial Officer

Phone: 240-654-1450

[email protected]

Investor Contact:

Lee Roth

Burns McClellan

Phone: 646-382-3403

[email protected]

Media Contact:

Danielle Cantey

Inizio Evoke, Biotech

Phone: 619-826-4657

[email protected]

This press release was published by a CLEAR® Verified individual.